Completed PHASE3 INTERVENTIONAL 4-arm NCT00849693

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder

Sponsor: Eli Lilly and Company

Conditions Major Depressive Disorder

Interventions Placebo duloxetine fluoxetine

Updated 7 times since 2017 Last updated: Mar 26, 2012 Started: Mar 31, 2009 Primary completion: Feb 28, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Major Depressive Disorder and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Albuquerque, United States , Aurora, United States , Austin, United States , Baltimore, United States , Bellevue, United States , Birmingham, United States , Bradenton, United States , Buenos Aires, Argentina , Carson, United States and 46 more locations